Dimensional Fund Advisors LP Purchases Shares of 11,870 Lipocine Inc. (NASDAQ:LPCN)

Dimensional Fund Advisors LP purchased a new stake in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent quarter.

Lipocine Price Performance

Shares of LPCN stock opened at $5.08 on Wednesday. The company has a market cap of $27.17 million, a price-to-earnings ratio of -2.97 and a beta of 1.22. The stock has a 50 day simple moving average of $4.27 and a 200-day simple moving average of $5.59. Lipocine Inc. has a 1-year low of $2.31 and a 1-year high of $11.79.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share for the quarter. The firm had revenue of $0.09 million during the quarter. Analysts anticipate that Lipocine Inc. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. StockNews.com raised Lipocine from a “hold” rating to a “buy” rating in a report on Monday. Alliance Global Partners began coverage on Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target for the company.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.